Stock Performance and Market Context
On the day the new low was recorded, Anuh Pharma’s stock price fell by 0.83%, underperforming its sector by 0.28%. This decline extends a three-day losing streak during which the stock has dropped by 3.67%. The share price now trades below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.
The broader market environment has also been challenging. The Sensex opened flat but closed down by 337.59 points, or 0.45%, at 82,869.79, approximately 3.97% below its 52-week high of 86,159.02. The index has experienced a three-week consecutive decline, losing 3.37% over this period. While the Sensex trades below its 50-day moving average, the 50DMA remains above the 200DMA, indicating some underlying resilience despite recent falls.
Long-Term Performance and Valuation Metrics
Over the past year, Anuh Pharma’s stock has underperformed significantly, delivering a negative return of 29.46%, in stark contrast to the Sensex’s positive 7.51% gain. The stock’s 52-week high was Rs.115, highlighting the extent of the recent decline.
Financially, the company’s long-term growth rates have been modest. Net sales have increased at an annualised rate of 13.69% over the last five years, while operating profit has grown at a slower pace of 7.18%. These figures reflect restrained expansion relative to sector peers.
While markets shift, this one's charging ahead! This Micro Cap from Aquaculture shows the strongest momentum signals in current conditions. Don't miss out on this ride!
- - Strongest current momentum
- - Market-cycle outperformer
- - Aquaculture sector strength
Recent Financial Results and Profitability
The company reported a Profit Before Tax (PBT) excluding other income of Rs.8.94 crores in the quarter ended September 2025, representing a decline of 29.3% compared to the average of the previous four quarters. Profit After Tax (PAT) for the latest six months stood at Rs.15.91 crores, down by 35.19%. Return on Capital Employed (ROCE) for the half-year was recorded at 15.90%, the lowest level observed in recent periods.
Despite these declines, Anuh Pharma maintains a low average debt-to-equity ratio of zero, indicating a debt-free capital structure. The company’s Return on Equity (ROE) remains at a moderate 11.8%, and it trades at a Price to Book Value ratio of 2.3, which is considered fair relative to its peers’ historical valuations.
However, profit contraction of 34.4% over the past year has contributed to the stock’s underperformance, even as the broader BSE500 index generated a positive return of 6.08% during the same period.
Shareholding and Promoter Activity
In a notable development, promoters have increased their stake in Anuh Pharma by 1.9% over the previous quarter, now holding 71.82% of the company’s equity. This rise in promoter shareholding may reflect confidence in the company’s strategic direction despite recent market setbacks.
Why settle for Anuh Pharma Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Mojo Score and Analyst Ratings
Anuh Pharma currently holds a Mojo Score of 28.0, categorised as a Strong Sell. This represents a downgrade from its previous Sell rating on 8 January 2026. The company’s Market Cap Grade is 4, reflecting its micro-cap status within the Pharmaceuticals & Biotechnology sector.
The downgrade to Strong Sell is primarily driven by the company’s subdued long-term growth, declining profitability metrics, and recent negative quarterly results. These factors have contributed to the stock’s sustained downward trajectory and its breach of the 52-week low.
Summary of Key Metrics
To summarise, Anuh Pharma’s stock has declined to Rs.71.6, its lowest level in a year, amid a challenging market backdrop and company-specific financial pressures. The stock’s performance contrasts with the broader market and sector indices, which have shown relative resilience. While the company maintains a clean balance sheet and reasonable valuation metrics, recent earnings declines and a weak growth profile have weighed on investor sentiment.
As of 20 January 2026, the stock’s three-day consecutive fall and trading below all major moving averages underscore the current bearish trend. The Sensex’s own recent weakness adds to the overall cautious environment for equities, particularly in the Pharmaceuticals & Biotechnology sector.
Investors and market participants will continue to monitor Anuh Pharma’s financial disclosures and market movements closely as the company navigates this period of subdued performance.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
